Skip to main content
impaact logo Return to homepage
  • Contact
    • Directory
  • About
    • Mission
    • Network Structure
      • Leadership
    • Areas of Research
      • Cure & Immunotherapy
      • Brain & Mental Health
      • Therapeutics
      • Tuberculosis
      • Social Behavioral Scientific Core (SBSC)
    • Early Career Investigator Program
    • Staff Spotlights
    • Funding Acknowledgements
    • Network Sites
      • Study Site Map
  • Studies
    • Research and Study Opportunities
    • Submit a Research Proposal
    • IMPAACT Study Snapshots
  • Community Engagement
    • ICAB Leadership Group
    • IMPAACT Community Advisory Board (ICAB)
    • Operations Center Staff
    • Resources
      • Acronyms
    • Site Community Advisory Boards
    • Community Meetings and Webinars
  • News & Events
    • Events and Conferences
    • IMPAACT Annual Meeting
    • Newsletters
    • Past Conference Presentations
    • Spotlight Series
  • Resources
    • COVID-19 Resources
    • HIV/AIDS Network Coordination (HANC)
    • Lab Center
      • Laboratory Committees
      • Laboratory Guidance Documents
      • Laboratory Resources for Quality Management
      • MiLab Resources
      • Specimen Repository
    • Manual of Procedures
    • Media Release Form
    • Network Logos & Templates
    • Regulatory Resources
    • Training Opportunities
    • NIH Updates
  • Publications
    • Abstracts
    • Manuscripts
  • Enter a search term.
Back to Directory

Andrew Wiznia

Email

andrew.wiznia@einsteinmed.org

Phone

718-918-4664

Institution

Jacobi Medical Center

Title

CRS Leader

Address

Jacobi Medical Center
1400 Pelham Parkway South
Building #1, Suite 1W5
Bronx, NY 10461
USA
Request an Update

Affiliated Studies

P1053: Evaluation PI-Containing vs. Non-PI-Containing Salvage Regimens.

DAIDS Number

10131

Research Area

Other

Study Status

Concluded

P1058A: Pharmacokinetics of New Classes of Antiretroviral Drug Combinations

DAIDS Number

10809

Research Area

Other

Study Status

Concluded

P1066: Raltegravir Safety, Tolerability, PK, & Antiretroviral Activity

DAIDS Number

10495

Research Area

Treatment

Study Status

Concluded

P1071: CCR5 Vicriviroc (SCH-417690)

DAIDS Number

10634

Research Area

N/A

Study Status

Concluded

P1090: Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Etravirine

DAIDS Number

10850

Research Area

Treatment

Study Status

Concluded
Show All
IMPAACT logo Return to homepage

Funded by the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute of Mental Health of the US National Institutes of Health, US Department of Health and Human Services.

Stay connected with the IMPAACT Network

Follow IMPAACT

Sign up for our newsletter

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Sitemap Privacy Notice

© 2020 IMPAACT Network